Remove RNA Remove Trials Remove Vaccine
article thumbnail

The Long Road to End Tuberculosis

Codon

Even after microbiologists discovered the bacterium that causes the illness in 1882, it wasn’t until the 1920s that researchers were able to develop a vaccine for TB. These breakthroughs have significantly curbed cases, with vaccination reducing the odds of death by 74 percent. tuberculosis , to develop the vaccine.

Vaccine 114
article thumbnail

Lexeo to help launch spinout around RNA drugs for the heart

BioPharma Drive: Drug Pricing

Published June 24, 2025 Gwendolyn Wu Senior reporter post share post print email license Lexeo Therapeutics and two life sciences investors are working together to launch a startup to develop cardiac RNA therapies. You can unsubscribe at anytime. Both programs are in early human studies.

RNA 219
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Levers for Biological Progress

Codon

Although Amodei does acknowledge some real-world issues limiting scientific progress — such as the slow growth of organisms and tedious clinical trials — he mostly passes over the more general tools that will be required to accelerate research in the near term. This essay focuses on how we might do both, specifically for the cell.

DNA 132
article thumbnail

Moderna COVID vaccine gets full approval for children

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Moderna COVID vaccine gets full approval for children The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., Kennedy Jr.

Vaccine 226
article thumbnail

The Access to Advanced Health Institute receives $18 million award to develop a temperature stable, single-dose chikungunya RNA vaccine through a phase 1 clinical trial

SCIENMAG: Medicine & Health

The Access to Advanced Health Institute Receives $18 Million Award to Develop a Temperature Stable, Single-Dose Chikungunya RNA Vaccine Through a Phase 1 Clinical Trial Credit: Delaney Brown Photography The Access to Advanced Health Institute Receives $18 Million Award to Develop a Temperature Stable, Single-Dose Chikungunya RNA Vaccine Through a Phase (..)

RNA 93
article thumbnail

mRNA Therapeutics: Revolutionizing Treatment Beyond Vaccines

DrugBank

Introduction Messenger RNA (mRNA) technology has emerged as one of the most significant medical breakthroughs. The COVID-19 pandemic brought mRNA to global prominence by developing highly effective vaccines by Moderna and Pfizer-BioNTech. mRNA-based cancer vaccines represent a groundbreaking innovation in oncology.

Vaccine 97
article thumbnail

Moderna Starts Dosing of Adolescents in Phase 2/3 COVID-19 Vaccine Trial

The Pharma Data

Moderna has begun dosing adolescents in a phase 2/3 trial evaluating messenger RNA-based vaccine candidate mRNA-1273 and plans to enroll 3,000 U.S. participants aged 12 to 17. Source link.

Vaccine 52